Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $5.1 million.

  • Anika Therapeutics' Net Cash Flow rose 74791.4% to $5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.4 million, marking a year-over-year increase of 4788.53%. This contributed to the annual value of -$15.7 million for FY2024, which is 1566.59% down from last year.
  • Latest data reveals that Anika Therapeutics reported Net Cash Flow of $5.1 million as of Q3 2025, which was up 74791.4% from -$549000.0 recorded in Q2 2025.
  • Anika Therapeutics' 5-year Net Cash Flow high stood at $5.6 million for Q3 2023, and its period low was -$14.7 million during Q2 2023.
  • In the last 5 years, Anika Therapeutics' Net Cash Flow had a median value of -$1.4 million in 2022 and averaged -$2.0 million.
  • Per our database at Business Quant, Anika Therapeutics' Net Cash Flow tumbled by 143330.31% in 2023 and then surged by 74791.4% in 2025.
  • Quarter analysis of 5 years shows Anika Therapeutics' Net Cash Flow stood at $3.3 million in 2021, then tumbled by 141.95% to -$1.4 million in 2022, then skyrocketed by 254.96% to $2.1 million in 2023, then tumbled by 337.34% to -$5.1 million in 2024, then surged by 200.91% to $5.1 million in 2025.
  • Its Net Cash Flow was $5.1 million in Q3 2025, compared to -$549000.0 in Q2 2025 and -$3.9 million in Q1 2025.